ReviewJournal of clinical medicine2022
Management of Acute Coronary Syndrome in Cancer Patients: It's High Time We Dealt with It.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta-Analysis.Clinical cardiology · 2025Pooled it
- ST-Segment Elevation Caused by Lung Cancer Mimicking STEMI.JACC. Case reports · 2026Article
- Five-year retrospective analysis of invasiveCardiovascular diagnosis and therapy · 2026Article
- Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study.Cardio-oncology (London, England) · 2025Article
- A Non-Stenting Approach to Left Main Thrombus in an Oncology Patient with Acute Heart Failure: A Case Report.The American journal of case reports · 2025Article
- Delving into the pinnacle: an in-depth analysis of the top 100 most cited articles on cardio-oncology.Hereditas · 2025Article
- Postdischarge cancer and mortality in patients with coronary artery disease: a retrospective cohort study.Journal of geriatric cardiology : JGC · 2025Article
- Cardiac Metastasis: Epidemiology, Pathophysiology, and Clinical Management.Life (Basel, Switzerland) · 2025Review
- Exploring the Perioperative Use of DOACs, off the Beaten Track.Journal of clinical medicine · 2024Review
- Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- The Impact of Geriatric Conditions in Elderly Patients with Coronary Heart Disease: A State-of-the-Art Review.Journal of clinical medicine · 2024Review
- The Development of a Chest-Pain Protocol for Women Presenting to the Emergency Department.CJC open · 2024Review
- What to Do When There Is Something Unexpected?Life (Basel, Switzerland) · 2024Article
- Predictive Model of Internal Bleeding in Elderly Aspirin Users Using XGBoost Machine Learning.Risk management and healthcare policy · 2024Article
- Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.Journal of clinical medicine · 2023Review
- Non-ST Elevation Myocardial Infarction in the Elderly. Antithrombotic Therapy and Beyond.Reviews in cardiovascular medicine · 2023Review
- Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Interplay between acute coronary syndromes and cancer: insights into pathophysiology, diagnostic challenges, and treatment options.Archives of medical sciences. Atherosclerotic diseases · 2023Article
- Editorial: Cardio-oncology: mechanisms and therapeutics.Frontiers in cardiovascular medicine · 2023Article
- Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients have an increased risk of cardiovascular disease and, notably, a significant prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence of cardiovascular risk factors in this setting leads to an interaction between these two conditions, influencing their therapeutic strategies and contributing to higher mortality. Nonetheless, cancer patients have generally not been evaluated in ACS trials, so that the treatment in these cases is still not fully known. We reviewed the current literature and discussed the best management for these very high-risk patients. The treatment strategy must be tailored based on the cancer type and stage, balancing thrombotic and bleeding risks. When the prognosis is longer than six months, especially if a clinical instability coexists, patients with ACS and cancer should be referred for percutaneous coronary intervention (PCI) as soon as possible. Moreover, an invasive strategy should be preferred in STEMI patients as well as in NSTEMI patients who are considered as high risk. On the contrary, in clinically stable NSTEMI patients, a conservative non-invasive strategy could be adopted, especially in cases of a poor life expectancy and/or of high risk of bleeding. Drug-Eluting-Stents (DES) should be the first choice if an invasive strategy is adopted. Conservative therapy could instead be considered in cancer patients with more stable CAD at an increased risk of major bleeding complications. However, the duration of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is recommended, but it should be as short as possible, whereas triple antithrombotic therapy is non-advised because it significantly increases the risk of bleeding. ACS management among cancer patients should be based on an accurate evaluation of the risk of thrombosis and bleeding. Future studies focused on choosing optimal strategies in tumor patients with ACS should be performed to treat this subset of patients better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.